Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
Antiviral Agents
/ therapeutic use
Bronchiolitis
/ epidemiology
Child
Gestational Age
Health Information Systems
Hospitalization
Humans
Infant
Infant, Newborn
Infant, Premature
Pediatrics
Respiratory Syncytial Virus Infections
/ drug therapy
Respiratory Syncytial Virus, Human
United States
/ epidemiology
bronchiolitis hospitalization
epidemiology
infants
palivizumab
respiratory syncytial virus
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
09
04
2020
accepted:
17
07
2020
pubmed:
22
7
2020
medline:
6
4
2022
entrez:
22
7
2020
Statut:
ppublish
Résumé
In 2014, the American Academy of Pediatrics stopped recommending palivizumab to otherwise healthy 29-34 weeks' gestational age (wGA) infants aged <12 months at respiratory syncytial virus (RSV) season start. Here, we compare the burden of RSV hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) before and after 2014 among otherwise healthy 29-34 wGA infants hospitalized at ≤6 months of age. A historical, observational cohort study was conducted to evaluate RSVH and BH in 29-34 wGA infants during the 2010-2017 RSV seasons using encounter data from 51 United States children's hospitals that comprise the Pediatric Health Information System. The overall cohort included 67 570 RSVH out of 96 281 patients with BH. wGA was known for 22 937 RSVH and 33 289 BH. For 29-34 wGA infants, there were 8.7% and 14.2% RSVH before and after 2014, respectively (P < .0001). Intensive care unit admissions increased for RSVH (from 54.5% to 64.2%; P = .0002) and BH (from 46.7% to 54.5%; P = .0005) after controlling for sex, race, comorbidity, and cluster. The total cost of care increased for RSVH from $37 million to nearly $60 million. RSVH, BH, and their severity increased among 29-34 wGA infants in the 3 RSV seasons following 2014.
Sections du résumé
BACKGROUND
In 2014, the American Academy of Pediatrics stopped recommending palivizumab to otherwise healthy 29-34 weeks' gestational age (wGA) infants aged <12 months at respiratory syncytial virus (RSV) season start. Here, we compare the burden of RSV hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) before and after 2014 among otherwise healthy 29-34 wGA infants hospitalized at ≤6 months of age.
METHODS
A historical, observational cohort study was conducted to evaluate RSVH and BH in 29-34 wGA infants during the 2010-2017 RSV seasons using encounter data from 51 United States children's hospitals that comprise the Pediatric Health Information System.
RESULTS
The overall cohort included 67 570 RSVH out of 96 281 patients with BH. wGA was known for 22 937 RSVH and 33 289 BH. For 29-34 wGA infants, there were 8.7% and 14.2% RSVH before and after 2014, respectively (P < .0001). Intensive care unit admissions increased for RSVH (from 54.5% to 64.2%; P = .0002) and BH (from 46.7% to 54.5%; P = .0005) after controlling for sex, race, comorbidity, and cluster. The total cost of care increased for RSVH from $37 million to nearly $60 million.
CONCLUSIONS
RSVH, BH, and their severity increased among 29-34 wGA infants in the 3 RSV seasons following 2014.
Identifiants
pubmed: 32691037
pii: 5874150
doi: 10.1093/infdis/jiaa435
pmc: PMC8974836
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1197-1204Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Pediatr. 2014 Oct;165(4):786-92.e1
pubmed: 25015578
Am J Perinatol. 2018 Jan;35(2):192-200
pubmed: 28881376
Pediatr Crit Care Med. 2012 Jul;13(4):407-14
pubmed: 22067984
Infect Dis Ther. 2017 Dec;6(4):477-486
pubmed: 28866800
PLoS One. 2018 Jul 24;13(7):e0200319
pubmed: 30040837
Clin Pediatr (Phila). 2015 Jun;54(6):594-7
pubmed: 25104728
BMC Health Serv Res. 2018 Apr 20;18(1):294
pubmed: 29678177
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Open Microbiol J. 2011;5:144-54
pubmed: 22262987
PLoS One. 2016 Apr 06;11(4):e0152208
pubmed: 27050095
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
PLoS One. 2017 Mar 2;12(3):e0172512
pubmed: 28253361
Am J Perinatol. 2020 Jan;37(2):174-183
pubmed: 31430818
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
J Med Econ. 2020 Feb;23(2):139-147
pubmed: 31432723
Am J Perinatol. 2018 Dec;35(14):1433-1442
pubmed: 29920638
J Am Heart Assoc. 2018 Jun 1;7(11):
pubmed: 29858364
Vaccine. 2020 Jan 10;38(2):251-257
pubmed: 31740097
Health Sci Rep. 2018 Oct 12;1(12):e91
pubmed: 30623050
Pediatr Cardiol. 2017 Aug;38(6):1311-1312
pubmed: 28536747
Pediatrics. 2014 Aug;134(2):415-20
pubmed: 25070315
J Card Fail. 2019 Jan;25(1):27-35
pubmed: 30485789
Pediatrics. 2015 Jan;135(1):e24-31
pubmed: 25489019
Pediatr Crit Care Med. 2017 May;18(5):442-451
pubmed: 28252524
Front Immunol. 2019 Sep 12;10:2152
pubmed: 31572372